Early Stage I-II (A-B) Prostate Cancer

Radiation Therapy Benefits Selected Patients With Node-Positive Prostate Cancer (10-13-2014)

According to a recent report published in The Journal of Clinical Oncology, men with advanced prostate cancer involving the lymph nodes may benefit from treatment with radiation in addition to hormonal therapy. Prostate cancer is the most commonly diagnosed... Continue Reading

Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients (10-1-2014)

REDWOOD CITY, Calif., Sept. 29, 2014 – Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with... Continue Reading

Advances in Genomic Testing-What you Need to Know (09-29-2014)

Q: What is genomic testing? A: Genomic testing looks at a group of genes and their varying levels of expression. This gene expression or activity can characterize how genes interact with one another and predict the behavior of certain tissues within... Continue Reading

New Survey Reveals that Prostate Cancer Impacts Sex Lives More than Any Other Aspect of Patients’ Lives (09-11-2014)

Washington, DC (September 8, 2014) – A recent survey conducted by ZERO – The End of Prostate Cancer and Ferring Pharmaceuticals Inc. aimed to uncover the impact of prostate cancer on patients, their caregivers, and the healthcare professionals (HCPs)... Continue Reading

Large Independent Validation Study Validates Oncotype DX Prostate Cancer Test (08-11-2014)

Genomic Health, Inc. announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts... Continue Reading

New Research Questions Early Prostate Cancer Treatment Options (07-28-2014)

Researchers at The University of Texas MD Anderson Cancer Center recently published their latest findings on the role a diagnosing urologist plays in deciding whether older men with low-risk prostate cancer should receive treatment for their disease,... Continue Reading

Data Demonstrates Benefit of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers (06-9-2014)

REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX® test and a new 16-gene panel to predict disease aggressiveness and clinical... Continue Reading

Radical Prostatectomy Offers Long-Term Benefit Over Watchful Waiting in Early Prostate Cancer (05-22-2014)

Researchers in Sweden recently reported in The New England Journal of Medicine that radical prostatectomy continues to show long-term benefits over watchful waiting in early prostate cancer. Follow up studies in the Scandinavian Prostate Group Cancer... Continue Reading

Recent Studies Find Oncotype DX® Can Reliably Predict Risk of Aggressive Prostate Cancer (05-22-2014)

Based on findings from three separate studies, it appears that the 17-gene Oncotype DX® Genomic Prostate Score (GPS) can help predict disease aggressiveness in prostate cancer at the time of diagnosis and therefore help physicians choose appropriate... Continue Reading

Radical Prostatectomy Shows Significant Long-Term Benefit in Early Prostate Cancer (03-18-2014)

Extended follow-up of the Scandinavian Prostate Cancer Group-4 trial (SPCG-4) has confirmed that radical prostatectomy is associated with a substantial reduction in mortality among men with early prostate cancer. These results were published in the New... Continue Reading

« Previous PageNext Page »